Summary and Pipeline
We aim to discover and develop medicines that are transformational for patients
Our programs span discovery-stage to late-stage development and cover a range of high-value indications including SerpinPC in hemophilia, orexin receptor 2 agonist program in sleep-wake disorders, and LockBody® technology platform in oncology.
We aim to pursue programs we believe could be first-in-class / best-in-class and where there is prior learning in human genetics or precedented human activity for a pathway of interest. Our approach is to pursue the best assets in a capital efficient manner and rapidly progress our programs through development, evaluating the unique biological advantage of our product candidates.
Centessa’s team is made up of pioneers in their fields working to advance our core programs. Read more on the inspiring stories of the continuing journeys from vision to transformational medicines below.
Realizing Our Vision
We are working to discover unique opportunities to potentially address key medical needs
SerpinPC in Hemophilia
Our hemophilia program has deep roots in the experiences of Dr. Trevor Baglin, an accomplished hematologist and Global Head of Hemophilia at Centessa. He was both inspired and driven to develop a drug that has the potential to change the current treatment paradigm for individuals living with hemophilia.
Click below to learn more about how our novel candidate, SerpinPC, has been designed with the potential to fulfill existing unmet needs.
Orexin Receptor 2 Agonist Program in Sleep-Wake Disorders
Trained as a bioengineer, Dr. Mario Alberto Accardi, President of the Centessa Orexin Program, saw the opportunity to use structure-based drug design to disrupt the conventional approach to treating sleep-wake disorders.
Click below to learn more about our orexin receptor 2 agonist program for sleep-wake disorders and other neurological conditions.
LockBody® Technology Platform in Oncology
Dr. William Finlay, President of the Centessa LockBody Program and a widely published expert on antibody engineering, developed the LockBody® technology platform with the goal to redefine immuno-oncology treatment for patients with cancer.
Click below to learn more about our novel LockBody® platform in oncology.
Pipeline
Potential first-in-class/best-in-class medicines
Asset
Indication
Preclinical
Phase 1
Phase 2
Registrational
SerpinPC
Activated Protein C (APC) Inhibitor
Hemophilia B
Fast Track Designation; Orphan Drug Designation
ORX142
Orexin Receptor 2 Agonist
Excessive Daytime Sleepiness (EDS)
In neurological, neurodegenerative & psychiatric conditions*
Centessa has other early-stage programs not reflected on this page.
NT1 is Narcolepsy Type1, NT2 is Narcolepsy Type 2, IH is Idiopathic Hypersomnia. *EDS in select neurological, neurodegenerative & psychiatric conditions.
